CRBU
Caribou Biosciences, Inc. NASDAQ Listed Jul 23, 2021$1.68
+7.01%
vs $1.57
Mkt Cap $156.9M
52w Low $1.25
27.0% of range
52w High $2.84
50d MA $1.98
200d MA $1.93
P/E (TTM)
—
EV/EBITDA
—
P/B
1.3x
Debt/Equity
0.2x
ROE
-121.2%
P/FCF
-1.4x
RSI (14)
32.40
ATR (14)
$0.13
Beta
2.46
50d MA
$1.98
200d MA
$1.93
Avg Volume
2.3M
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
2929 7th Street · Berkeley, CA 94710 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.33 | -0.26 | +21.2% | 1.88 | +1.1% | +3.2% | +4.6% | +0.0% | +4.4% | +0.9% | — |
| Mar 5, 2026 | AMC | -0.33 | -0.28 | +15.2% | 1.71 | -2.9% | +6.4% | +8.2% | +3.0% | -3.0% | -4.1% | — |
| Nov 12, 2025 | AMC | -0.36 | -0.30 | +16.7% | 2.26 | +1.8% | -11.9% | +0.0% | -5.0% | -1.1% | -2.7% | — |
| Aug 12, 2025 | AMC | -0.40 | -0.35 | +12.5% | 1.79 | -3.9% | +8.9% | +2.6% | -1.0% | -5.6% | -5.3% | — |
| May 8, 2025 | AMC | -0.43 | -0.43 | +0.0% | 0.79 | +0.0% | -2.0% | +5.7% | -4.3% | +4.6% | +2.6% | — |
| Mar 10, 2025 | AMC | -0.40 | -0.39 | +2.5% | 1.11 | +0.9% | -3.6% | -0.9% | -7.0% | +2.5% | +1.0% | — |
| Nov 6, 2024 | AMC | -0.44 | -0.38 | +13.6% | 2.75 | -3.6% | +1.1% | -3.6% | +4.1% | -15.8% | -6.4% | — |
| Aug 6, 2024 | AMC | -0.45 | -0.42 | +6.7% | 1.96 | +3.6% | -3.1% | +6.3% | -4.0% | -4.6% | +0.5% | — |
| May 7, 2024 | AMC | -0.39 | -0.46 | -17.9% | 3.73 | -2.4% | -6.2% | +4.3% | -3.0% | +4.8% | -1.9% | — |
| Mar 11, 2024 | AMC | -0.22 | -0.39 | -77.3% | 7.22 | -0.8% | -30.5% | +11.6% | -4.3% | +0.2% | -2.6% | — |
| Nov 7, 2023 | AMC | -0.38 | -0.12 | +68.4% | 4.77 | +4.4% | -5.0% | -12.9% | -2.4% | -1.6% | +11.3% | — |
| Aug 8, 2023 | AMC | -0.49 | -0.48 | +2.0% | 6.54 | +2.3% | +5.8% | +4.2% | -3.5% | -3.6% | -1.9% | — |
| May 9, 2023 | AMC | -0.48 | -0.46 | +4.2% | 4.40 | +2.3% | +6.8% | -6.8% | -3.9% | +6.9% | -5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.94 | -0.5% | -4.6% | +4.8% | +0.5% | -1.5% | +1.0% |
| Mar 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $1.82 | $1.79 | -1.6% | +8.2% | +3.0% | -3.0% | -4.1% | -0.5% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.28 | +5.1% | +0.9% | -2.3% | -2.3% | -1.0% | +8.2% |
| Nov 3 | Citigroup | Maintains | Buy → Buy | — | $2.42 | $3.40 | +40.5% | +0.4% | -10.7% | +0.9% | -2.3% | -2.3% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.77 | $0.77 | -0.5% | -0.3% | +10.4% | -0.2% | -5.8% | +9.8% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.95 | $0.96 | +1.1% | +0.1% | +5.2% | +4.0% | -1.9% | -5.8% |
| Jan 7 | BofA Securities | Maintains | Buy → Buy | — | $1.88 | $1.92 | +2.1% | -0.5% | -8.0% | -4.7% | -5.5% | +0.6% |
| Nov 26 | Citigroup | Maintains | Buy → Buy | — | $2.02 | $2.51 | +24.3% | +0.0% | +8.9% | -0.5% | +8.2% | -8.4% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.09 | $2.12 | +1.4% | -4.8% | -0.5% | +0.5% | -1.5% | +1.0% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $2.17 | +0.5% | -8.3% | -4.0% | -3.7% | -6.0% | +2.9% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.86 | $1.85 | -0.5% | +2.2% | +9.5% | +0.5% | +4.3% | -2.3% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $1.96 | $2.03 | +3.6% | -3.1% | +6.3% | -4.0% | -4.6% | +0.5% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.73 | $2.64 | -3.3% | -3.3% | -9.1% | -4.2% | +0.9% | +3.4% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.09 | -2.8% | +0.9% | -2.3% | -1.4% | -6.7% | -3.6% |
| May 16 | Truist | Maintains | Buy → Buy | — | $3.64 | $3.66 | +0.5% | -1.4% | -5.6% | -7.7% | -1.3% | +0.6% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $3.60 | +1.7% | +4.8% | -1.9% | +0.0% | -1.4% | -5.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.23 | $5.39 | +3.1% | +3.1% | +1.7% | -4.2% | -0.4% | +1.1% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $7.22 | $7.16 | -0.8% | -30.5% | +11.6% | -4.3% | +0.2% | -2.6% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.57 | $6.53 | -0.6% | +1.2% | -4.1% | +7.1% | +5.3% | +1.7% |
| Jul 14 | Truist | Maintains | Buy → Buy | — | $8.14 | $6.81 | -16.3% | -22.6% | -0.2% | +9.9% | -2.9% | -1.3% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.50 | +2.3% | +6.8% | -6.8% | -3.9% | +6.9% | -5.6% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.33 | $5.54 | +3.9% | -2.4% | -0.8% | -2.3% | -1.6% | -1.6% |
| Mar 10 | RBC Capital | Maintains | Outperform → Outperform | — | $5.51 | $5.54 | +0.5% | -6.0% | +2.9% | -2.4% | -0.8% | -2.3% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.51 | $5.54 | +0.5% | -6.0% | +2.9% | -2.4% | -0.8% | -2.3% |
| Aug 29 | Citigroup | Maintains | Buy → Buy | — | $10.23 | $9.94 | -2.8% | -2.6% | -4.3% | +3.6% | +6.6% | -6.4% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.41 | $10.36 | -0.5% | -0.8% | -2.6% | -1.6% | +5.7% | +6.4% |
| Aug 10 | RBC Capital | Maintains | Outperform → Outperform | — | $8.14 | $8.11 | -0.4% | +14.3% | +1.0% | +5.5% | +1.1% | +7.3% |
| May 13 | Citigroup | Maintains | Buy → Buy | — | $8.10 | $8.42 | +4.0% | +10.7% | +8.6% | -0.7% | -5.7% | -5.3% |
| May 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.63 | $6.52 | -1.7% | +22.2% | +10.7% | +8.6% | -0.7% | -5.7% |
| May 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.67 | $7.00 | +4.9% | +9.3% | -9.1% | +22.2% | +10.7% | +8.6% |
| Mar 22 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.15 | $9.34 | +2.1% | +9.5% | -4.2% | -0.9% | -3.0% | +1.3% |
| Feb 18 | RBC Capital | Maintains | Outperform → Outperform | — | $10.22 | $10.40 | +1.8% | -2.2% | -2.5% | -5.4% | +6.7% | +0.3% |
| Feb 14 | Brookline Capital | Maintains | Buy → Buy | — | $10.71 | $10.80 | +0.8% | +2.8% | +5.3% | -1.9% | -10.1% | -2.2% |
| Dec 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.59 | $19.61 | +5.5% | -8.9% | +6.4% | -5.2% | -0.9% | +11.0% |
| Nov 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.05 | $18.05 | +5.9% | +9.0% | -8.9% | +6.4% | -5.2% | -0.9% |
| Nov 15 | Citigroup | Upgrade | Neutral → Buy | — | $21.70 | $22.45 | +3.5% | +0.1% | -0.9% | +3.3% | -7.1% | +3.0% |
| Aug 17 | Citigroup | Maintains | Neutral → Neutral | — | $26.48 | $26.19 | -1.1% | -8.2% | +11.3% | -6.0% | +2.6% | +12.1% |
| Aug 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $26.48 | $26.19 | -1.1% | -8.2% | +11.3% | -6.0% | +2.6% | +12.1% |
| Aug 17 | BofA Securities | Maintains | Buy → Buy | — | $26.48 | $26.19 | -1.1% | -8.2% | +11.3% | -6.0% | +2.6% | +12.1% |
No insider trades available.
8-K
Caribou Biosciences, Inc. -- 8-K Filing
Jun 18
8-K · 8.01
!! High
Caribou Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 11
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CRBU's 8-K filing appears incomplete, but as a clinical-stage CRISPR biotech company, investors should monitor upcoming announcements for trial results or regulatory milestones that could significantly impact valuations.
Mar 31
8-K
Caribou Biosciences, Inc. -- 8-K Filing
Caribou Biosciences reported 2025 financial results and provided a business update, with the company advancing its CRISPR genome-editing pipeline toward clinical milestones.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Pfizer Inc | 4,690,431 | $8M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 3,767,228 | $7M | New | Mar 2026 |
| 3 | Renaissance Technologies Llc | 2,590,497 | $5M | Added | Mar 2026 |
| 4 | Two Sigma Investments, Lp | 1,759,934 | $3M | Added | Mar 2026 |
| 5 | Bank Of America Corp /de/ | 1,297,167 | $2M | Added | Mar 2026 |
| 6 | Aberdeen Group Plc | 1,212,541 | $2M | Reduced | Mar 2026 |
| 7 | Marshall Wace, Llp | 1,205,668 | $2M | Added | Mar 2026 |
| 8 | Millennium Management | 1,074,421 | $2M | Added | Mar 2026 |
| 9 | Acadian Asset Management Llc | 925,039 | $2M | Added | Mar 2026 |
| 10 | Susquehanna International Group, Llp | 836,903 | $2M | Reduced | Mar 2026 |
| 11 | Fmr Llc | 723,959 | $1M | — | Mar 2026 |
| 12 | Maverick Capital Ltd | 652,542 | $1M | — | Mar 2026 |
| 13 | Morgan Stanley | 596,912 | $949K | Reduced | Dec 2025 |
| 14 | 72 Investment Holdings, Llc | 474,067 | $754K | — | Dec 2025 |
| 15 | Green Alpha Advisors, Llc | 373,650 | $710K | — | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 303,655 | $577K | New | Mar 2026 |
| 17 | Ubs Group Ag | 259,169 | $492K | Reduced | Mar 2026 |
| 18 | Bruce & Co., Inc. | 250,000 | $475K | — | Mar 2026 |
| 19 | Jane Street Group, Llc | 295,685 | $470K | Reduced | Dec 2025 |
| 20 | Northern Trust Corp | 217,735 | $414K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$156.9M
Enterprise Value
$17.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.28x
P/B
1.28x
P/S
14.00x
P/FCF
-1.40x
EV/EBITDA
—
Shares Out
93.4M
Financials (TTM)
Revenue
$11.2M
Net Income
-$133.2M
EBITDA
-$112.0M
Free Cash Flow
-$112.4M
Op Cash Flow
-$111.0M
EPS Basic
$-1.59
EPS Diluted
$-1.42
EPS Forward
$-1.23
Gross Margin
82.6%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$175.4M
Total Liab.
$53.2M
Total Equity
$122.2M
Cash
$139.3M
LT Debt
$0
Book Value/Sh
$1.31
Debt/Equity
0.22x
Current Ratio
5.71
Quick Ratio
5.71
Returns & Growth
ROE
-121.2%
ROA
-84.5%
ROIC
-89.8%
Rev Growth YoY
+11.7%
EPS Growth YoY
+3.6%
Price Returns
2W
+10.3%
1M
+25.5%
3M
+24.2%
6M
+21.6%
12M
+122.6%
Technicals
52W High
$2.84
52W Low
$1.25
50d MA
$1.98
200d MA
$1.93
RSI (14)
32.40
ATR (14)
$0.13
Beta
2.46
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.00
High
$7.00
Low
$7.00
Median
$7.00
Data updated apr 25, 2026 3:04am
· Source: financialmodelingprep.com